Received: 7 April 2020
Accepted: 19 August 2020
First Online: 14 September 2020
Ethics approval and consent to participate
: All patients provided their written informed consent and were prospectively included in the ethics committee-approved ALCINA study (NCT02866149), investigating the feasibility of analysis of circulating tumor markers in blood in various early- or advanced-stage malignancies.
: Not applicable.
: Mattias Bergqvist is an employee of Biovica.The Circulating Tumor Biomarkers Laboratory received a research grant from Biovica.The other authors have no disclosures.